# Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

> **NCT05130983** · PHASE1 · TERMINATED · sponsor: **Direct Biologics, LLC** · enrollment: 3 (actual)

## Conditions studied

- Crohn Disease
- Inflammatory Bowel Diseases

## Interventions

- **BIOLOGICAL:** ExoFlo

## Key facts

- **NCT ID:** NCT05130983
- **Lead sponsor:** Direct Biologics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-23
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Enrollment challenges.
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130983, "Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05130983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*